Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Cash from Financing Activities for 14 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 431.25% year-over-year to $1.7 million, compared with a TTM value of -$10.4 million through Sep 2025, down 340.07%, and an annual FY2024 reading of -$13.6 million, down 305.11% over the prior year.
  • Cash from Financing Activities was $1.7 million for Q3 2025 at Fennec Pharmaceuticals, up from -$284000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $19.8 million in Q3 2022 and bottomed at -$12.2 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $1.4 million, with a median of $257000.0 recorded in 2024.
  • The sharpest move saw Cash from Financing Activities surged 1186.67% in 2023, then tumbled 686.53% in 2024.
  • Year by year, Cash from Financing Activities stood at $5.0 million in 2021, then tumbled by 83.41% to $824000.0 in 2022, then soared by 595.39% to $5.7 million in 2023, then plummeted by 313.12% to -$12.2 million in 2024, then surged by 114.32% to $1.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for FENC at $1.7 million in Q3 2025, -$284000.0 in Q2 2025, and $359000.0 in Q1 2025.